CRO

Q2-2019 Outsourced Pharma Services Update– The CDMO sector has continued to consolidate at a rapid pace, particularly in North America. Specialist providers in biologics and gene therapy are receiving competitive valuations, while API and FDF competence continues to motivate acquirers.

Cannabis, Hemp Producers Targeted in May Health-Care Deals – The health-care industry is getting into the weed business.

Consolidation in Outsourced Pharmaceutical Services– Contract Research Organizations (CROs) and Contract Development & Manufacturing Organizations (CDMOs) are utilizing strategic mergers, acquisitions, and private equity partnerships to capitalize on tailwinds in the outsourced pharmaceutical services sector.

Health-Care Deals Steady, Strong Through First Third of 2019– Consistency is the name of the game for health-care industry transactions in 2019 so far.

INSIGHT: Health Care M&A Transactions on Pace to Set Record in 2019– March madness is over for college basketball fans, but it’s just the beginning of a fast-paced year for health-care M&A activity.

Q1-2019 Pharmaceutical CDMO & CRO Update– North America has continued to be a focal point for strategic consolidators. International CROs and CDMOs are expanding their North American footprints via strategic mergers, acquisitions, and asset deals.

Long-Term Care Deals Dominate Health Industry in February– The long-term care sector continued its domination of health-care deals in February, Bloomberg Law’s transactions advisory board says.

Healthcare Services M&A: A 2018 Recap and Expectations for 2019 – Episode 8 of Provident’s Healthcare Dealcast

The Health-Care M&A Meter: Hot 2018 to Be Followed by Hotter 2019– The outlook for health-care mergers and acquisitions in 2019 suggests even more transactions this year as compared to 2018, with activity in the hospital and health system sector expected to continue, as well as increasing volume of deals in the physician services, home health. and health-care IT sectors.

Health-Care Info Tech Companies Make Moves in November– Health-care information technology companies stole the deal spotlight in November, setting up end-of-year numbers rivaling those of the long-term care, physician practice, and health and hospital system sectors.

Q4-2018 CRO Update – The Contract Research market continues to demonstrate substantial growth, in large part due to increasing demand for services in clinical trials between Phases II and IV, which account for the majority of the industry’s revenue. Private equity was the driving force behind much of the consolidation in 2018 and the fourth quarter was no different with two of the three transactions involving a private equity or PE-backed acquirer.

  • “Provident listened to our story, confirmed that our business was valuable and made us feel like this was the only transaction important to them.”

  • ”I have a tremendous amount of appreciation and gratitude to the Provident team for their hard work and diligence throughout this process. Each and every member of the Provident team is excellent at their jobs and it has been a pleasure working with such a professional team. Provident has provided outstanding guidance and counsel, and this deal could never have gotten done without Provident’s leadership.”

  • “Provident’s depth of experience and practical business savvy was demonstrated in their ability to cut through what sometimes looked like impasse.”

  • “We would not have been successful navigating the process without Provident’s hard work and active participation. They exceeded our expectations and we would highly recommend them to any health care company seeking a knowledgeable and engaged investment banking firm.”

  • “A lot of investment bankers were interviewed, Provident was chosen. Provident delivered. My clients could not be happier.”

  • “While the decision to sell our business was a difficult one, Provident vigilantly represented and protected our best interests throughout the transaction.  Provident was the right choice for Cascade and I would recommend their services to anyone.”

  • “After working with Provident on several transactions, it is evident that their extensive industry knowledge and deal expertise prove to be invaluable to their clients.”